9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Items 101–200 of 958
Real‐world performance of the MiniMed™ 670G system in Europe
Da Silva, J., Bosi, E., Jendle, J., Arrieta, A., Castaneda, J., Grossman, B., Cordero, T. L., Shin, J., & Cohen, O. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14424 · Cited by 60
Nargesi, A. A., Jeyashanmugaraja, G. P., Desai, N., Lipska, K., Krumholz, H., & Khera, R. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021084 · Cited by 61
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 65
Venkatachalapathy, P., Padhilahouse, S., Sellappan, M., Subramanian, T., Kurian, S. J., Miraj, S. S., Rao, M., Raut, A. A., Kanwar, R. K., Singh, J., et al. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s329787 · Cited by 80
Pradhan, R., Yin, H., Yu, O. H. Y., & Azoulay, L. (2022) · Diabetes Care · doi:10.2337/dc21-1953 · Cited by 62
Zhang, H., Wang, Y., Chen, C., Lu, Y., & Wang, N. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001513 · Cited by 61
McCoy, R. G., Van Houten, H. K., Karaca-Mandic, P., Ross, J. S., Montori, V. M., & Shah, N. D. (2021) · Diabetes Care · doi:10.2337/dc20-2977 · Cited by 57
Venkatraman, S., Echouffo-Tcheugui, J. B., Selvin, E., & Fang, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.47656 · Cited by 60
Janež, A., Muzurović, E. M., Bogdański, P., Czupryniak, L., Fábryová, Ľ., Fras, Z., Guja, C., Haluzík, M., Kempler, P., Lalic, N. M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01615-5 · Cited by 69
“Drugs that both treat hyperglycaemia and facili‑ tate BW loss, especially GLP‑1 RAs and SGLT2is, should be considered in patients with diabetes and obesity [157, 158].”
BackgroundSarkar, S., & Brown, T. T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01382-8 · Cited by 59
“assess the need for additional therapy [25], although as noted above, hemoglobin A1c may not be accurate in PWH.”
BackgroundInfluentialDenicolò, S., Perco, P., Thöni, S., & Mayer, G. J. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107931 · Cited by 56
Diagnostic strategies and clinical management of lipodystrophy
Foss‐Freitas, M. C., Akıncı, B., Luo, Y., Stratton, A., & Oral, E. A. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1735360 · Cited by 55
Ming, J., Yu, X., Xu, X., Wang, L., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00942-7 · Cited by 52
“Although various anti-diabetic drugs have been developed and used to treat diabetes, side effects and long-term efficacy pose frequent challenges [2].”
BackgroundJude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?
Wong, E., & Kroon, L. A. (2021) · Clinical Diabetes · doi:10.2337/cd20-0119 · Cited by 58
Folkerts, K., Petruski‐Ivleva, N., Kelly, A., Fried, L. F., Blankenburg, M., Gay, A., & Kovesdy, C. P. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.12.1506 · Cited by 62
Yang, C.-Y., Chen, Y.-R., Ou, H.-T., & Kuo, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01211-4 · Cited by 51
Smith, F. N. C., Sabri, A. H. B., Heppel, M., Fonseca, I., Chowdhury, F., Cheung, K., Willmor, S., Rawson, F. J., & Marlow, M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122234 · Cited by 52
“Currently, the American Diabetes Association and the European Association for the Study of Diabetes recommend metformin as the first-line oral agent when diabetes is unsuccessfully controlled through lifestyle choices (American Diabetes Association, 2020; Inzucchi et al., 2015; NICE, 2020).”
Adult-onset autoimmune diabetes in 2020: An update
Maddaloni, E., Moretti, C., Mignogna, C., & Buzzetti, R. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.04.014 · Cited by 53
Cahn, A., Wiviott, S. D., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., Rozenberg, A., Wilding, J. P. H., Leiter, L. A., Bhatt, D. L., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14179 · Cited by 51
Morton, J. I., Ilomäki, J., Magliano, D. J., & Shaw, J. E. (2020) · Diabetologia · doi:10.1007/s00125-020-05304-3 · Cited by 52
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 53
Nutrition and Obesity in the Pathogenesis of Youth-Onset Type 1 Diabetes and Its Complications
March, C. A., BECKER, D. J., & Libman, I. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.622901 · Cited by 52
Low-Carbohydrate and Very-Low-Carbohydrate Diets in Patients With Diabetes
Merrill, J. D., Soliman, D., Kumar, N., Lim, S., Shariff, A. I., & Yancy, W. S. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0070 · Cited by 49
Colosimo, S., Ravaioli, F., Petroni, M. L., Brodosi, L., Marchignoli, F., Barbanti, F. A., Sasdelli, A. S., Marchesini, G., & Pironi, L. (2021) · Liver International · doi:10.1111/liv.14799 · Cited by 45
Insulin: evolution of insulin formulations and their application in clinical practice over 100 years
Bolli, G. B., CHENG, A. Y. Y., & Owens, D. R. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01938-4 · Cited by 56
Frequency of interruptions to sitting time: benefits for postprandial metabolism in type 2 diabetes
Homer, A. R., Taylor, F. C., Dempsey, P. C., Wheeler, M. J., Sethi, P., Townsend, M. K., Grace, M. S., Green, D. J., Cohen, N. D., Larsen, R. N., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1410 · Cited by 49
Anderson, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0031 · Cited by 47
Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.13731 · Cited by 44
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & De Jonghe, B. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 49
Goyal, S., Rani, J., Bhat, M. A., & Vanita, V. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.656 · Cited by 53
Dejgaard, T. F., von Scholten, B. J., Christiansen, E., Kreiner, F. F., Bardtrum, L., von Herrath, M., Mathieu, C., Madsbad, S., & ADJUNCT ONE and ADJUNCT TWO Investigators (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14532 · Cited by 48
Hua, R., Ding, N., Guo, H., Wu, Y., Yuan, Z., & Li, T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.918167 · Cited by 48
Jain, A. B., Kanters, S., Khurana, R., Kissock, J., Severin, N., & Stafford, S. G. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00984-x · Cited by 47
Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis
Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C., & Sun, E. C. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2024.7082 · Cited by 47
Barriers to Type 1 Diabetes Adherence in Adolescents
Azar, S., Jaoude, N. M. A., Kędzia, A. W., & Niechciał, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195669 · Cited by 54
Yang, A., Wu, H., Lau, E. S. H., Ronald, C. W., Kong, A. P. S., So, W. Y., Luk, A. O. Y., Chan, J. C. N., & Chow, E. (2020) · Diabetes Care · doi:10.2337/dc20-0260 · Cited by 50
Higher Global Diet Quality Score Is Inversely Associated with Risk of Type 2 Diabetes in US Women
Fung, T. T., Li, Y., Bhupathiraju, S. N., Bromage, S., Batis, C., Holmes, M. D., Stampfer, M. J., Hu, F. B., Deitchler, M., & Willett, W. C. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab195 · Cited by 50
Barbarawi, M., Al‐Abdouh, A., Barbarawi, O., Lakshman, H. G., kasasbeh, M. A., & Chen, K. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10083-z · Cited by 48
Stoian, A. P., Sachinidis, A. G., Stoica, R. A., Nikolić, D., Patti, A. M., & Rizvi, A. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154295 · Cited by 48
Diabetes and coronary artery disease: not just a risk factor
Grant, P. J., Cosentino, F., & Marx, N. (2020) · Heart · doi:10.1136/heartjnl-2019-316243 · Cited by 47
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Al Yami, M. S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01070-z · Cited by 41
Scisciola, L., Rizzo, M. R., Cataldo, V., Fontanella, R. A., Balestrieri, M. L., D’Onofrio, N., Marfella, R., Paolisso, G., & Barbieri, M. (2020) · The FASEB Journal · doi:10.1096/fj.202000860rr · Cited by 46
Galindo, R. J., Ramos, C., Cardona, S., Vellanki, P., Davis, G. M., Oladejo, O., Albury, B., Dhruv, N., Peng, L., & Umpierrez, G. E. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211033837 · Cited by 43
Emirates Diabetes Society Consensus Guidelines for the Management of Type 2 Diabetes Mellitus – 2020
Alawadi, F., Abusnana, S., Afandi, B. O., Aldahmani, K. M., Hajeri, O. M. A., Aljaberi, K., Alkaabi, J., Al-Madani, A., Bashier, A. M., Beshyah, S., et al. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000506508 · Cited by 48
Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
DeJong, C., Masuda, C., Chen, R., Kazi, D. S., Dudley, R. A., & Tseng, C.-W. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2922 · Cited by 42
Current trends in diabetes mellitus database research in Japan
Kohsaka, S., Morita, N., Okami, S., Kidani, Y., & Yajima, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14325 · Cited by 46
Challenges and strategies for managing diabetes in the elderly in long-term care settings
Pandya, N., Hames, E., & Sandhu, S. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0018 · Cited by 42
Wang, Y., Jia, X., & Cong, B. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1396031 · Cited by 50
Yu, O. H. Y., Dell’Aniello, S., Shah, B. R., Brunetti, V. C., Daigle, J.-M., Fralick, M., Douros, A., Hu, N., Alessi‐Severini, S., Fisher, A., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0267 · Cited by 49
Baviera, M., Genovese, S., Lepore, V., Colacioppo, P., Robusto, F., Tettamanti, M., D'Ettorre, A., Avanzini, F., Fortino, I., Nicolucci, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14361 · Cited by 42
Lingvay, I., Kirk, A. R., Lophaven, S., Wolden, M. L., & Shubrook, J. H. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01010-4 · Cited by 41
Type 2 Diabetes and the Microbiome
Barlow, G. M., & Mathur, R. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac184 · Cited by 49
Zhao, T., Yang, Q., Feuerbacher, J. F., Yu, B., Brinkmann, C. K., Cheng, S., Bloch, W., & Schumann, M. (2024) · British Journal of Sports Medicine · doi:10.1136/bjsports-2024-108127 · Cited by 45
“Metformin and exercise training are both considered first-line treatments for T2DM 6 7 and have been shown to be effective in preventing diabetes in some trials on high-risk individuals.”
Exploring the Correlation and Protective Role of Diabetes Mellitus in Aortic Aneurysm Disease
Arun, D., Munir, W., Schmitt, L. V., Vyas, R., Ravindran, J. I., Bashir, M., Williams, I. M., Velayudhan, B. V., & Mohammed Idhrees, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.769343 · Cited by 43
Wright, E. E., Morgan, K., Fu, D. K., Wilkins, N., & Guffey, W. J. (2020) · Clinical Diabetes · doi:10.2337/cd20-0042 · Cited by 40
Easing the Financial Burden of Diabetes Management: A Guide for Patients and Primary Care Clinicians
Herges, J. R., Neumiller, J. J., & McCoy, R. G. (2021) · Clinical Diabetes · doi:10.2337/cd21-0004 · Cited by 38
Troncone, A., Cascella, C., Chianese, A., Zanfardino, A., Piscopo, A., Borriello, A., Casaburo, F., del Giudice, E. M., & Iafusco, D. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.556520 · Cited by 45
“…females have a desire for thinness, males prefer to be thinner or larger), and different corresponding DEBs could be recognized (i.e., excessive exercise vs. restraint activities for weight loss) (McCabe and Ricciardelli, 2004; Lawler and Nixon, 2011; d’Emden et al., 2013; Araia et al., 2017).”
BackgroundAndreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
Momordica balsamina: phytochemistry and pharmacological potential of a gifted species
Ramalhete, C., Gonçalves, B. M. F., Barbosa, F., Duarte, N., & Ferreira, M. U. (2022) · Phytochemistry Reviews · doi:10.1007/s11101-022-09802-7 · Cited by 43
Zhou, Y., Zhang, Y., Zhang, R., Zhou, Y., Li, N., Wang, M., Tian, H., & Li, S. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001407 · Cited by 41
Spinetti, G., Mutoli, M., Greco, S., Riccio, F., Ben‐Aicha, S., Kenneweg, F., Jusić, A., de Gonzalo‐Calvo, D., Nossent, A. Y., Novella, S., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01842-3 · Cited by 38
Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
Cowart, K. (2020) · Clinical Diabetes · doi:10.2337/cd19-0061 · Cited by 33
Laichuthai, N., Abdul‐Ghani, M. A., Kosiborod, M., Parksook, W. W., Kerr, S. J., & DeFronzo, R. A. (2020) · Diabetes Care · doi:10.2337/dc20-0059 · Cited by 44
Wright, E. E., & Aroda, V. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798127 · Cited by 47
A salivary microbiome-based auxiliary diagnostic model for type 2 diabetes mellitus
Liu, Y., Chen, V., He, J., Zheng, X. M., Xu, X., & Zhou, X. (2021) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2021.105118 · Cited by 43
Segar, M. W., Patel, K. V., Hellkamp, A. S., Vaduganathan, M., Lokhnygina, Y. V., Green, J. B., Wan, S., Kolkailah, A. A., Holman, R. R., Peterson, E. D., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024094 · Cited by 42
Dagogo-Jack, S., Pratley, R. E., Cherney, D. Z. I., McGuire, D. K., Cosentino, F., Shih, W. J., Liu, J., Frederich, R., Mancuso, J. P., Raji, A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002484 · Cited by 37
The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review
Wu, C.-N., & Tien, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9368583 · Cited by 40
Lisco, G., Tullio, A. D., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., & Triggiani, V. (2020) · Endocrine · doi:10.1007/s12020-020-02444-9 · Cited by 39
Mody, R., Yu, M., Nepal, B., Konig, M., & Grabner, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14195 · Cited by 35
Mirabelli, M., Chiefari, E., Tocci, V., Caroleo, P., Giuliano, S., Greco, E., Luque, R. M., Puccio, L., Foti, D. P., Aversa, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050985 · Cited by 37
A Review on the Efficacy and Safety of Oral Semaglutide
Niman, S., Hardy, J., Goldfaden, R. F., Reid, J., Sheikh‐Ali, M., SUTTON, D. R., & Choksi, R. R. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00341-8 · Cited by 43
Dutta, A., Bhansali, A. K., & Rastogi, A. (2021) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346211033458 · Cited by 41
Yan, H., Huang, C., Shen, X., Li, J., Zhou, S., & Li, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.923606 · Cited by 37
Nair, R., Mody, R., Yu, M. B., Cowburn, S., Кониг, М., & PREWITT, T. G. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01320-1 · Cited by 39
Significant impact of time-of-day variation on metformin pharmacokinetics
Türk, D., Scherer, N., Selzer, D., Dings, C., Hanke, N., Dallmann, R., Schwab, M. G., Timmins, P., Nock, V., & Lehr, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05898-4 · Cited by 37
Khera, R., Schuemie, M. J., Lu, Y., Ostropolets, A., Chen, R., Hripcsak, G., Ryan, P. B., Krumholz, H. M., & Suchard, M. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057977 · Cited by 37
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
Rojano‐Toimil, A., & Ciudin, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173955 · Cited by 38
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
“Sulphonylureas, another long-standing class of glucose-lowering agents, are effective and inexpensive [10].”
Repurposing Metformin for Cancer Treatment: A Great Challenge of a Promising Drug
Saengboonmee, C., Sanlung, T., & Wongkham, S. (2021) · Anticancer Research · doi:10.21873/anticanres.15410 · Cited by 36
Humanin and diabetes mellitus: A review of in vitro and in vivo studies
Boutari, C., Pappas, P. D., Theodoridis, T. D., & Vavilis, D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i3.213 · Cited by 37
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Matthews, D., Del Prato, S., Mohan, V., Mathieu, C., Vencio, S., Chan, J. C. N., Stumvoll, M., & Paldánius, P. M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00926-7 · Cited by 35
Stottlemyer, B. A., McDermott, M. C., Minogue, M. R., Gray, M. P., Boyce, R. D., & Kane‐Gill, S. L. (2023) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986231181334 · Cited by 37
New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment
Haddad, D., Dsouza, V. S., Al‐Mulla, F., & Madhoun, A. S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010571 · Cited by 37
“However, these therapies have limitations, such as insufficient efficacy or the potential for adverse events (AEs), including hypoglycemia, weight gain, gastrointestinal discomfort, urinary tract infection, or heart failure [13–16].”
BackgroundZügner, E., Yang, H., Kotzbeck, P., Boulgaropoulos, B., Sourij, H., Hagvall, S., Elmore, C. S., ESTERLINE, R. L., Moosmang, S., Oscarsson, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147966 · Cited by 35
Hussain, A., Ramsey, D. J., Lee, M., Mahtta, D., Khan, M. S., Nambi, V., Ballantyne, C. M., Petersen, L. A., Walker, A. D., Kayani, W. T., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.024 · Cited by 46
Leohr, J. K., Dellva, M. A., Carter, K., LaBell, E. S., & Linnebjerg, H. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01030-0 · Cited by 34
Steenkamp, D., Eby, E. L., Gulati, N., & Liao, B. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821997923 · Cited by 33
Sia, H.-K., Kor, C.-T., Tu, S.-T., Liao, P.-Y., & Wang, J.-Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-81024-x · Cited by 33
Sinha, B., & Ghosal, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01062-6 · Cited by 34
The role of SGLT-2 inhibitors in managing type 2 diabetes
Tsushima, Y., Lansang, M. C., & Makin, V. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20088 · Cited by 37
Htoo, P. T., Buse, J. B., Cavender, M. A., Wang, T., Pate, V., Edwards, J. K., & Stürmer, T. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022376 · Cited by 35
Review of Associations Between Type 2 Diabetes and Cancer
Bonagiri, P. R., & Shubrook, J. H. (2020) · Clinical Diabetes · doi:10.2337/cd19-0077 · Cited by 33
Gao, F., Lv, X., Mo, Z., Ma, J., Zhang, Q., Yang, G., Liu, W., Li, Q., Zhou, J., Bao, Y., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14163 · Cited by 37
Danne, T., Schweitzer, M. A., Keuthage, W., Kipper, S., Kretzschmar, Y., Simon, J., Wiedenmann, T., & Ziegler, R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0360 · Cited by 33
Chen, T., Li, Y., Chen, S., Lin, Y., Sun, C., Chen, D., Mao, C., Michael Shengtao, W. U., Chang, C., Chu, P., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01169-3 · Cited by 32
The Influence of Anti-Diabetic Drugs on Prostate Cancer
Knura, M., Garczorz, W., Borek, A., Drzymała, F., Rachwał, K., George, K., & Francuz, T. (2021) · Cancers · doi:10.3390/cancers13081827 · Cited by 37
Lipid effects of glucagon-like peptide 1 receptor analogs
Berberich, A. J., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000750 · Cited by 32
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.